Fintel reports that on January 23, 2025, Piper Sandler initiated coverage of Bright Minds Biosciences (NasdaqCM:DRUG) with a ...

Bright Minds Biosciences Inc. (NASDAQ:DRUG) has been able to initiate its phase 2 BREAKTHROUGH study using its 5-HT2C agonist BMB-101 for the treatment of adult patients with classic Absence ...

The average Revenue of companies in the Sector is 663.5 M with a standard deviation of 2.237 B. Bright Minds Biosciences Inc's Revenue of - ranks in the - percentile for the Sector. The following ...

Equities researchers at Cantor Fitzgerald issued their FY2025 EPS estimates for Bright Minds Biosciences in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan ...

Discover the top-performing biotech stocks in 2024! From oncology to psychedelics some companies showed remarkable results.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

1 Day DRUG 0.90% DJIA 0.31% Russell 2K 0.21% Health Care/Life Sciences -1.12% ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

After hours: 7:59:10 p.m. EST ...